Article
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Journal for immunotherapy of cancer - 1 May 2020
Hurkmans Daan P, Basak Edwin A, Schepers Nina, Oomen-De Hoop Esther, Van der Leest Cor H, El Bouazzaoui Samira, Bins Sander, Koolen Stijn L W, Sleijfer Stefan, Van der Veldt Astrid A M, Debets Reno, Van Schaik Ron H N, Aerts Joachim G J V, Mathijssen Ron H J
Abstract excerpt
BACKGROUND: A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even when these activated effector cells are released from their immune checkpoint brake. Hence, in this study we aimed to assess the association of baseline serum...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.